SOURCE: Chembio Diagnostics, Inc.

December 05, 2005 09:00 ET

Chembio to Present at the Friedland Investment Events Micro Cap Conference Tuesday, December 6th at 11:55 AM (EST)

MEDFORD, NY -- (MARKET WIRE) -- December 5, 2005 -- Larry Siebert, Chairman, President and CEO, of Chembio Diagnostics, Inc. (OTC BB: CEMI), will speak at the Friedland Investment Events Micro Cap Conference Tuesday, December 6th at 11:55 AM (EST) in the Doubletree Metropolitan Hotel located in midtown Manhattan.

Mr. Siebert will review the Company's progress towards FDA approval for its rapid HIV tests and upcoming regulatory, marketing and operational milestones. Chembio's rapid HIV tests include the HIV 1/2 STAT-PAK™, HIV 1/2 STAT-PAK Dipstick and the HIV 1/2 SURE CHECK®. These tests are simple, safe, cost-effective and operator friendly requiring less than five microliters of blood from a fingerstick. Chembio's investor presentation is available through its Web site at www.chembio.com under "Investors."

The Friedland conference is open to brokers, analysts, fund managers and various investors who are interested in Biotech, Medical & Healthcare companies. The conference aims to provide presenting companies the opportunity to meet with institutional investors, corporate executives and experts from scientific and medical communities.

ABOUT CHEMBIO

Chembio Diagnostics, Inc. (Chembio) possesses expertise in the development and manufacturing of rapid test products for various infectious diseases, including HIV, Tuberculosis and Chagas Disease. References to Chembio Diagnostics, Inc. may actually refer to Chembio Diagnostic Systems, Inc.; the 100%-owned subsidiary of Chembio Diagnostics, Inc. Chembio is located at 3661 Horseblock Road, Medford, NY 11763.

Contact Information

  • IR Contact:
    Richard Larkin
    Tel: (631) 924-1135
    Chembio Diagnostics, Inc.
    ir@chembio.com